Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery

PURPOSE: KPI-121 is a nanoparticle suspension of loteprednol etabonate with improved ocular pharmacokinetics compared with marketed formulations. The efficacy and safety of KPI-121 1% ophthalmic suspension (INVELTYS™) dosed twice daily (BID) were evaluated in participants who had undergone cataract...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Terry, Sall, Kenneth, Holland, Edward J, Brazzell, R Kim, Coultas, Susan, Gupta, Preeya K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311334/
https://www.ncbi.nlm.nih.gov/pubmed/30643381
http://dx.doi.org/10.2147/OPTH.S185800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311334/
https://www.ncbi.nlm.nih.gov/pubmed/30643381
http://dx.doi.org/10.2147/OPTH.S185800

Ejemplares similares